The Tweets and Yelps of an Overvalued Market
Both Twitter and Yelp were priced for hypergrowth that now looks less certain.
China's Thumb on Fed Rate-Rise Scale
The Federal Reserve is trying to balance the outlook for jobs and inflation as it considers a rate increase. China’s market turmoil could weigh on its deliberations.
Gilead: the Apple of the Biotech World
Gilead faces short-term challenges as its hepatitis C franchise slows. But the stock is a rare example of biotech value.
Boardroom Soap Opera at P&G Hasn't Helped Shares
Ahead of the Tape: A.G. Lafley’s return to Procter & Gamble didn’t revive its fortunes as hoped.
Barclays Returns More Mysterious Than Bankable
Barclays was expected to explain how it will hit higher return targets in its latest set of results, but detail is still lacking.
Investors Need to Check Peugeot's Speed
Peugeot has done well in cutting costs and maintaining pricing discipline. But the outlook is getting tougher for the French carmaker.
As China's Stock Market Boils, Yuan Will Stay Cool
A weaker yuan may make economic sense, but Beijing can hardly afford a bout of currency weakness on top of everything else.
Twitter Must Lead, Not Follow, on User Growth
Twitter recognizes it has a growth problem but it will be hard to fix.
Pfizer's Dollar Dilemma Adds Pressure for Deal Making
Pfizer’s strong results were undermined by currency effects—which also raise pressure to do a deal.
Rental Demand Supplies Home-Building Opportunity
A tight market is pushing rents higher, but new supply is on the way.
BP Still Needs to Drill Business for Cash
BP has been active in cutting in response to the lower oil price environment. Its mixed success just reflects the challenge for the oil and gas sector.
Don't Check Out of Marriott
Ahead of the Tape: Like surging Airbnb, Marriott International has an enviable asset-light approach to lodging.
Zurich Insurance Bid for RSA Would Be a Gamble
U.K.-based insurer RSA has big uncertainties around capital, pensions and profitability.
Baidu's Reinvention Leaves Investors Searching for Profits
Baidu is investing heavily in new services to keep pace with rivals, eating up profits in the process.
GlaxoSmithKline Needs More Quiet Victories
The U.K. pharmaceuticals company has had repeated problems in recent years. It needs consistent, if unremarkable, performance from here.
Allergan's Healthy Price May Come With Side Effects
While investors are excited about Allergan’s pursuit of more deals, they have to hope it doesn’t bite off more than it can chew.
China Stock-Market Recovery Goes All Wobbly
The dam Beijing hastily built to hold back the selloff has sprung a major leak.
Twitter Is No Bargain
Ahead of the Tape: Twitter’s recent stumble creates the appearance of a possible bargain compared with rival social network Facebook, but the gulf between them is vast.
Teva's Allergan Deal Looks a Healthier Mouthful
Teva’s $40.5 billion deal to buy Allergan’s generics business looks a lower risk option than its hostile pursuit of Mylan.
copyright © 2015 Dow Jones & Company, Inc.